Table 1. The baseline characteristics of the enrolled cohort.
| Double dose LPV/r (800 mg/200 mg) 12 hourly(n = 11) | Additional ritonavir(400 mg/400 mg) hourly(n = 7) | Total(n = 18) | |
| WeightMedian (IQR) | 56 (53.5–59) kg | 59.1 (61.2–70) kg | 57 (54–63) kg |
| CD4-count1Median (IQR) | 80 (37–424) cells/mm3 | 145 (88–167) cells/mm3 | 111(41–181) cells/mm3 |
| Viral load2 | <40 copies per ml: n = 3 | <40 copies per ml: n = 3 | <40 copies per ml: n = 6 |
| ≥40 copies per ml: n = 6 | ≥40 copies per ml: n = 4 | ≥40 copies per ml: n = 10 | |
| unknown: n = 2 | unknown: n = 2 | ||
| Duration on LPV/r prior to tuberculosis treatment | 4 (2–25) months | 11 (9–31) months | 10 (4–32) months |
| Median (IQR) | (n = 3) | (n = 5) | (n = 8) |
| Duration on tuberculosis treatment prior to LPV/r initiation | 2 (1–2) months | 1 month | 1.5 (1–2) months |
| Median (IQR)3 | (n = 7) | (n = 2) | (n = 9) |
| Month of tuberculosis treatment when enrolled, by patient | Patient 1 = 3 | Patient 8 = 3 | Median (IQR) = 4 (2–5) |
| Patient 2 = 7 | Patient 9 = 3 | ||
| Patient 3 = 4 | Patient 10 = 1 | ||
| Patient 4 = 2 | Patient 11 = 3 | ||
| Patient 5 = 4 | Patient 12 = 3 | ||
| Patient 6 = 2 | Patient 13 = 6 | ||
| Patient 7 = 6 | Patient 14 = 4 | ||
| Median(IQR) = 4 (2–4.5) | Patient 15 = 4 | ||
| Patient 16 = 4 | |||
| Patient 17 = 5 | |||
| Patient 18 = 2 | |||
| Median (IQR) = 4 (2.5–5) | |||
| Number of pharmacokinetic measurements during study period, by patient | Patient 1 = 3 | Patient 8 = 3 | Median (IQR) = 3 (2–4) |
| Patient 2 = 2 | Patient 9 = 3 | ||
| Patient 3 = 1 | Patient 10 = 1 | ||
| Patient 4 = 5 | Patient 11 = 3 | ||
| Patient 5 = 1 | Patient 12 = 3 | ||
| Patient 6 = 5 | Patient 13 = 6 | ||
| Patient 7 = 3 | Patient 14 = 4 | ||
| Median (IQR) = 3 (2–4) | Patient 15 = 4 | ||
| Patient 16 = 4 | |||
| Patient 17 = 5 | |||
| Patient 18 = 2 | |||
| Median (IQR) = 3 (3–4) |
1
CD4-counts were collected from the clinical record. We recorded the last CD4-count prior to study enrolment.
2
Viral load measurements were collected from the clinical record. We recorded the last viral load prior to study enrolment that was done within 6 months of tuberculosis diagnosis and treatment.
3
One patient was started on LPV/r-based ART and tuberculosis treatment on the same day in the double dose LPV/r group.